Literature DB >> 20624940

Regulatory B cells (B10 cells) and regulatory T cells have independent roles in controlling experimental autoimmune encephalomyelitis initiation and late-phase immunopathogenesis.

Takashi Matsushita1, Mayuka Horikawa, Yohei Iwata, Thomas F Tedder.   

Abstract

Experimental autoimmune encephalomyelitis (EAE) is a T lymphocyte-mediated autoimmune disease of the CNS. Significant roles for B cells and a rare IL-10-producing CD1d(high)CD5(+) regulatory B cell subset (B10 cells) have been identified during the initiation and progression of EAE. Whether and how the regulatory functions of B10 cells and FoxP3(+) T regulatory cells (Tregs) overlap or influence EAE immunopathogenesis independently has remained unanswered. This study demonstrates that the number of endogenous or adoptively transferred B10 cells directly influenced EAE pathogenesis through their production of IL-10. B10 cell numbers expanded quickly within the spleen, but not CNS following myelin oligodendrocyte glycoprotein(35-55) immunization, which paralleled B10 cell regulation of disease initiation. The adoptive transfer of myelin oligodendrocyte glycoprotein(33-35)-sensitized B10 cells into wild-type mice reduced EAE initiation dramatically. However, B10 cells did not suppress ongoing EAE disease. Rather, Treg numbers expanded significantly within the CNS during disease progression, which paralleled their negative regulation of late-phase disease. Likewise, the preferential depletion of B10 cells in vivo during disease initiation enhanced EAE pathogenesis, whereas Treg depletion enhanced late-phase disease. B10 cells did not regulate T cell proliferation during in vitro assays, but significantly altered CD4(+) T cell IFN-gamma and TNF-alpha production. Furthermore, B10 cells downregulated the ability of dendritic cells to act as APCs and thereby indirectly modulated T cell proliferation. Thus, B10 cells predominantly control disease initiation, whereas Tregs reciprocally inhibit late-phase disease, with overlapping B10 cell and Treg functions shaping the normal course of EAE immunopathogenesis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20624940      PMCID: PMC3717968          DOI: 10.4049/jimmunol.1001307

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  62 in total

1.  To 'B' regulated: B cells as members of the regulatory workforce.

Authors:  Pau Serra; Pere Santamaria
Journal:  Trends Immunol       Date:  2005-11-21       Impact factor: 16.687

2.  Novel suppressive function of transitional 2 B cells in experimental arthritis.

Authors:  Jamie G Evans; Karina A Chavez-Rueda; Ayad Eddaoudi; Almut Meyer-Bahlburg; David J Rawlings; Michael R Ehrenstein; Claudia Mauri
Journal:  J Immunol       Date:  2007-06-15       Impact factor: 5.422

3.  Development of psoriasis after B cell depletion with rituximab.

Authors:  Shouvik Dass; Edward M Vital; Paul Emery
Journal:  Arthritis Rheum       Date:  2007-08

4.  Inhibitory role of CD19 in the progression of experimental autoimmune encephalomyelitis by regulating cytokine response.

Authors:  Takashi Matsushita; Manabu Fujimoto; Minoru Hasegawa; Kazuhiro Komura; Kazuhiko Takehara; Thomas F Tedder; Shinichi Sato
Journal:  Am J Pathol       Date:  2006-03       Impact factor: 4.307

5.  IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice.

Authors:  Keith L Knutson; Yushe Dang; Hailing Lu; Jason Lukas; Bond Almand; Ekram Gad; Ehizoje Azeke; Mary L Disis
Journal:  J Immunol       Date:  2006-07-01       Impact factor: 5.422

6.  CD22 ligand binding regulates normal and malignant B lymphocyte survival in vivo.

Authors:  Karen M Haas; Suman Sen; Isaac G Sanford; Ann S Miller; Jonathan C Poe; Thomas F Tedder
Journal:  J Immunol       Date:  2006-09-01       Impact factor: 5.422

7.  Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation.

Authors:  Thomas Korn; Jayagopala Reddy; Wenda Gao; Estelle Bettelli; Amit Awasthi; Troels R Petersen; B Thomas Bäckström; Raymond A Sobel; Kai W Wucherpfennig; Terry B Strom; Mohamed Oukka; Vijay K Kuchroo
Journal:  Nat Med       Date:  2007-03-25       Impact factor: 53.440

8.  B cell regulation of CD4+CD25+ T regulatory cells and IL-10 via B7 is essential for recovery from experimental autoimmune encephalomyelitis.

Authors:  Monica K Mann; Katarzyna Maresz; Leah P Shriver; Yanping Tan; Bonnie N Dittel
Journal:  J Immunol       Date:  2007-03-15       Impact factor: 5.422

9.  Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis.

Authors:  Martin Duddy; Masaaki Niino; Femina Adatia; Sherry Hebert; Mark Freedman; Harry Atkins; Ho Jin Kim; Amit Bar-Or
Journal:  J Immunol       Date:  2007-05-15       Impact factor: 5.422

10.  The inflamed central nervous system drives the activation and rapid proliferation of Foxp3+ regulatory T cells.

Authors:  Richard A O'Connor; Katy H Malpass; Stephen M Anderton
Journal:  J Immunol       Date:  2007-07-15       Impact factor: 5.422

View more
  169 in total

1.  CD19+IgM+ cells demonstrate enhanced therapeutic efficacy in type 1 diabetes mellitus.

Authors:  Andrew D Vonberg; Maria Acevedo-Calado; Aaron R Cox; Susan L Pietropaolo; Roberto Gianani; Steven K Lundy; Massimo Pietropaolo
Journal:  JCI Insight       Date:  2018-12-06

2.  B cell depletion therapy exacerbates murine primary biliary cirrhosis.

Authors:  Amy Dhirapong; Ana Lleo; Guo-Xiang Yang; Koichi Tsuneyama; Robert Dunn; Marilyn Kehry; Thomas A Packard; John C Cambier; Fu-Tong Liu; Keith Lindor; Ross L Coppel; Aftab A Ansari; M Eric Gershwin
Journal:  Hepatology       Date:  2010-12-28       Impact factor: 17.425

3.  Regulatory B cell production of IL-10 inhibits lymphoma depletion during CD20 immunotherapy in mice.

Authors:  Mayuka Horikawa; Veronique Minard-Colin; Takashi Matsushita; Thomas F Tedder
Journal:  J Clin Invest       Date:  2011-10-24       Impact factor: 14.808

Review 4.  L2pB1: a new player in autoimmunity.

Authors:  Xuemei Zhong; Thomas L Rothstein
Journal:  Mol Immunol       Date:  2010-12-31       Impact factor: 4.407

5.  Ischemic transient neurological events identified by immune response to cerebral ischemia.

Authors:  Glen C Jickling; Xinhua Zhan; Boryana Stamova; Bradley P Ander; Yingfang Tian; Dazhi Liu; Shara-Mae Sison; Piero Verro; S Claiborne Johnston; Frank R Sharp
Journal:  Stroke       Date:  2012-02-02       Impact factor: 7.914

6.  Enhanced renewal of regulatory T cells in relation to CD4(+) conventional T lymphocytes in the peripheral compartment.

Authors:  Jeane de Souza Nogueira; Fábio Barrozo do Canto; Caroline Fraga Cabral Gomes Nunes; Pedro Henrique Oliveira Vianna; Luciana de Souza Paiva; Alberto Nóbrega; Maria Bellio; Rita Fucs
Journal:  Immunology       Date:  2015-12-17       Impact factor: 7.397

7.  Regulatory T and B lymphocytes in a spontaneous autoimmune polyneuropathy.

Authors:  S Quan; J R Sheng; P M Abraham; B Soliven
Journal:  Clin Exp Immunol       Date:  2016-02-04       Impact factor: 4.330

Review 8.  The role of B cells in multiple sclerosis: Current and future therapies.

Authors:  Austin Negron; Rachel R Robinson; Olaf Stüve; Thomas G Forsthuber
Journal:  Cell Immunol       Date:  2018-10-21       Impact factor: 4.868

9.  ICAM1+ neutrophils promote chronic inflammation via ASPRV1 in B cell-dependent autoimmune encephalomyelitis.

Authors:  Ryder F Whittaker Hawkins; Alexandre Patenaude; Aline Dumas; Rajiv Jain; Yodit Tesfagiorgis; Steven Kerfoot; Takeshi Matsui; Matthias Gunzer; Patrice E Poubelle; Catherine Larochelle; Martin Pelletier; Luc Vallières
Journal:  JCI Insight       Date:  2017-12-07

10.  An increase in tolerogenic dendritic cell and natural regulatory T cell numbers during experimental autoimmune encephalomyelitis in Rras-/- mice results in attenuated disease.

Authors:  Avijit Ray; Sreemanti Basu; Nichole M Miller; Andrew M Chan; Bonnie N Dittel
Journal:  J Immunol       Date:  2014-04-25       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.